SHANGHAI, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its “XingShi” Large Language Model (“XS LLM”) was featured by Nature News under the headline “A Chinese AI tool can manage chronic disease — could it revolutionize health care?” The article, written by science reporter Mohana Basu, cited the model’s potential applications for chronic disease management, while citing expert commentary. Xinhua ...

据了解，作为方舟健客的"超级数字大脑"，杏石大模型驱动着AI用药助手、AI健康管家、AI医生助 手、AI学术助手和AI搜索5大应用。每款应用可分别针对临床与患者端的特定场景，在诸如用药指导、 患者教育、诊断辅助及医学文献查询等领域实现实时精准辅助。例如，AI学术助手产品通过搭配语音 交互功能支持专家级答案秒级语音播报，契合临床医生忙碌的诊疗场景，提升了工具使用效率和黏性。 报道指出，近年来以大模型为代表的新一轮AI技术浪潮兴起。方舟健客也及时捕捉到了行业发展趋 势，并开展了相应探索。今年9月，方舟健客杏石大模型正式落地，不仅吸引到医疗领域的关注，其创 新模式更被国外学者敏锐捕捉，首次登上了Nature报道。 智通财经APP获悉，方舟健客(06086)涨超8%，截至发稿，涨8.23%，报4.34港元，成交额4077.62万港 元。 消息面上，据动脉网报道，近日，Nature的新闻版面刊登了一则关于中国医疗大模型的报道，引发行业 广泛关注。Nature报道中所提及的中国慢病管理模式，是全球范围内较少的、将AI与多种慢性疾病管理 深度融合且取得较好成绩的典型案例。目前海外市场中，将AI+多种慢病管理深度融合且有较大 ...

Group 1 - The core viewpoint of the articles highlights the significant rise of Ark Health (方舟健客) stock, which increased by 8.23% to HKD 4.34, with a trading volume of HKD 40.77 million, following a report in Nature about China's medical AI models [1] - The Nature report emphasizes China's chronic disease management model, which integrates AI with various chronic disease management practices, showcasing a successful case that is rare globally [1] - The report indicates that while there are few large-scale companies in the overseas market that deeply integrate AI with chronic disease management, China's innovative forces are emerging in this field, potentially allowing for a leapfrog development [1] Group 2 - Ark Health's "super digital brain," the Xing Shi model, drives five major applications: AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - Each application provides real-time and precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries [2] - The AI academic assistant product enhances efficiency and user engagement by offering expert-level answers with voice interaction capabilities, catering to the busy clinical environment of doctors [2]

方舟云康控股有限公司 F angzhou I n c . 股份代號 : 6086 中期報告 2025 目錄 2 釋義及行業詞彙表 5 公司資料 7 重點摘要 9 管理層討論與分析 23 企業管治及其他資料 33 審閱簡明綜合財務報表報告 34 綜合損益及其他全面收益表 35 綜合財務狀況表 37 綜合權益變動表 38 簡明綜合現金流量表 39 未經審核中期財務報告附註 釋義及行業詞彙表 「Crescent Point」 指 Crescent China Investment Management Ltd.，一家於2020年10月28日在英屬 維爾京群島註冊成立及由英屬維爾京群島金融服務委員會規管的私募股權管理公 司，由非執行董事David McKee HAND先生最終控制；或如文義另有所指，就某 些歷史事件而言，指Crescent Fund Management Pte. Ltd.，一家於2012年12月 17日在新加坡註冊成立及新加坡金融管理局轄下的持牌投資管理公司 「Crescent Point投資實體」 指 Crescent Trident Singapore Pte. Ltd.、Asia-Pac E- ...

Core Insights - Fangzhou Inc. was recognized as an "Outstanding Growth Story in Hong Kong Stocks" at the China Capital Market Development Forum, highlighting its exceptional performance in technology innovation and earnings growth [1][2] Company Performance - In its 2025 interim results, Fangzhou reported revenue of RMB 1.5 billion, an increase of 12.9% year-on-year [3] - The net profit reached RMB 12.5 million, marking profitability for the period, while adjusted net profit climbed 16.8% to RMB 17.6 million, a record high [3] - The registered user base expanded by 15.8% to 52.8 million, with 11.9 million monthly active users, up 34.4% year-on-year [3] - The number of registered doctors reached 229,000, and the paid user repurchase rate stood at 85.4% [3] Technological Advancements - Fangzhou launched its proprietary "XingShi" Large Language Model (XS LLM) aimed at improving chronic disease management [4][5] - The XS LLM integrates multimodal capabilities, including image and speech recognition, natural language processing, and large-scale medical knowledge storage [6] - The model supports five domain-specific intelligent agents, creating a closed-loop service architecture for chronic disease management [6][7] Strategic Partnerships - Fangzhou announced strategic partnerships with Innovent Biologics and Zhejiang Otsuka Pharmaceutical to advance digital health management [8] - The company aims to leverage its AI technology and platform operations to build new digital health collaboration models, contributing to the "Healthy China 2030" initiative [8] Industry Context - The China Capital Market Development Forum gathered nearly 1,000 representatives from regulators, industry, and investment sectors to discuss opportunities for China's capital markets [9]

Core Insights - Fangzhou Inc. received the "Excellence Award" at Gilead Sciences' 2025 Multi-Channel Conference, recognizing its innovation in AI-driven Internet healthcare solutions [1][2] - The collaboration between Fangzhou and Gilead focuses on enhancing chronic disease management and improving patient outcomes through digital health solutions [3][6] Company Achievements - Fangzhou's AI technology has significantly advanced chronic disease management, as highlighted by Dr. Xie Fangmin during the conference [2][4] - The company serves 52.8 million registered users and 229,000 physicians, positioning itself as a leader in online chronic disease management in China [8] Strategic Collaborations - Fangzhou and Gilead are working together on disease prevention, treatment, and digital chronic care services, aligning their visions for better health outcomes [3][6] - The launch of Gilead's initiative "Together for Health" aims to enhance patient-centric services, with Fangzhou pledging to contribute to this integrated ecosystem [4][6] Future Directions - Fangzhou plans to leverage its AI technology and chronic disease management services while integrating Gilead's expertise in areas such as HIV and oncology to explore new care models [6]

Core Insights - Fangzhou Inc. received the "Excellence Award" at Gilead Sciences' 2025 Multi-Channel Conference, recognizing its achievements in AI-driven Internet healthcare solutions [1][2] - The award highlights Fangzhou's commitment to innovation and digitalization in healthcare, particularly in chronic disease management [2][4] - Fangzhou aims to deepen collaboration with Gilead to combine advanced therapies with digital health expertise for scalable care solutions [2][6] Company Overview - Fangzhou Inc. is China's leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [8] - The company specializes in tailored medical care and AI-enabled precision medicine solutions [8] Collaboration with Gilead - Fangzhou and Gilead have closely collaborated in disease prevention, treatment, and digital chronic care services, aligning their visions for improved patient outcomes [4][6] - The conference featured the launch of Gilead's initiative "Together for Health," which aims to enhance patient-centric services and strengthen digital-enabled care [5][6] Future Directions - Fangzhou plans to leverage its AI technology and full-cycle chronic disease management services while integrating Gilead's expertise in HIV, viral hepatitis, and oncology [6] - The company is exploring new "AI+ chronic care" models to advance public health [6]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 根據上市規則第13.10條作出之公告 經作出在相關情況下有關本公司的該等合理查詢後，董事會確認(i)新聞稿所 含資料並不構成根據上市規則第13.09(2)條或香港法例第571章證券及期貨條 例第XIVA部項下之內幕消息條文所規定之內幕消息；及(ii)其亦並不知悉股 份交易價格上升之任何理由，或為避免股份出現虛假市場而須作出公告之任 何資料，或須予披露之任何內幕消息。 本公司股東及潛在投資者於買賣股份時務請審慎行事。 本公告乃根據本公司之命令而作出。董事會就本公告之準確性全體及個別承 擔責任。 承董事會命 方舟云康控股有限公司 主席 謝方敏先生 香港，2025年9月14日 本公告乃應香港聯合交易所有限公司（「聯交所」）要求根據聯交所證券上市 規則（「上市規則」）第13.10條作出。方舟云康控股有限公 ...

Core Insights - The article emphasizes that chronic disease management in China is entering a new era driven by AI, highlighting the importance of technology in addressing healthcare challenges posed by an aging population [1][2] - The online chronic disease management market in China is projected to grow significantly, with a compound annual growth rate of 44.5%, from 45.5 billion yuan in 2023 to 600 billion yuan by 2030 [1] - Ark Health's AI-driven approach aims to create a patient-centered healthcare model, leveraging technology to enhance doctor-patient relationships and improve service efficiency [2][3] Technology Development - Ark Health's "Xing Shi Medical Model" is designed to integrate various intelligent components into a collaborative service team, aiming for state-of-the-art performance [3] - The AI assistant has reportedly saved doctors over 60,000 hours of time through its diagnostic and case analysis capabilities [3] - The company has developed five core AI products, including AI Medication Finder and AI Health Manager, which aim to enhance clinical decision-making and knowledge dissemination [4] Strategic Collaborations - Ark Health has formed strategic partnerships with pharmaceutical companies, such as Innovent Biologics, to target the rapidly growing weight management market, which is expected to reach 149 billion yuan by 2030 [6][7] - The collaboration with Innovent focuses on integrating AI technology with innovative weight loss products, providing comprehensive support for patients [6][8] - The partnership with Zhejiang Otsuka Pharmaceutical aims to enhance drug service offerings and health education through AI capabilities [7][8]

Major Events - China Power (02380) plans to acquire a 31% stake in Dazhou Energy [1] - Shun Teng International Holdings (00932) received a 20% discount from Chairman Zhang Shaohui for a full acquisition offer [1] - Huajian Medical (01931) established a joint venture to deepen the global blockchain financial ecosystem strategy through the "ETHK" core brand [1] - Derin Holdings (01709) signed a strategic cooperation and investment agreement with Winner Fashion (03709) [1] - Dongwu Cement (00695) major shareholder Goldview intends to sell a total of 204 million shares, making Hong Kong Aviation the single largest shareholder [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYH2066 tablets in China [1] - GAC Group (02238) plans to issue up to 15 billion yuan in corporate bonds and 15 billion yuan in medium-term notes [1] - Huatai Securities (06886) plans to issue up to 6 billion yuan in corporate bonds [1] - Ark Health (06086) stated that the H2H conference news is not insider information and is unaware of the reason for the stock price increase [1] Financial Data - China Resources Land (01109) reported a cumulative contract sales amount of 136.8 billion yuan for the first eight months, a year-on-year decrease of 12.0% [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 73.011 billion yuan for the first eight months, a year-on-year increase of approximately 3.7% [1] - Zhong An Online (06060) reported a total original insurance premium income of approximately 23.625 billion yuan for the first eight months, a year-on-year increase of 6.36% [1]